Among the different new cancer therapies, magnetic hyperthermia and photothermal therapy are arguably the most promising technology. Both methods consist of infiltrating nanoparticles into the tumours, which then generate heat upon a stimulus. The generated heat will then burn the tumour from the inside out. As this effect is kept local, systemic side effects, which are typical for traditional treatments (eg. chemo- or radiotherapy) and often agonizing for the affected people, are avoided. For both treatment methods products are under FDA evaluation or already approved by the FDA and more and more research is dedicated to these techniques.
It is obvious that the applied nanoparticles must be exceedingly effective in regard to their dose-response properties to keep pharmacological dosages minimal and therapeutic efficacy maximal. However, this factor varies significantly within synthetic batches, even (or in particular) in commercial-scale production. Control and validation procedures guaranteeing this quality are neither conducted nor offered by most nanoparticle suppliers. This leaves the consumer, e.g. the researcher or medical doctor, with the burden to follow up on it.
NanoLockin’s underlying measurement principle is based on lock-in thermography, a method widely used in engineering due to its exceptional sensitivity. In a nutshell: the nanoparticle sample temperature is periodically varied while an infrared imaging device records its surface temperature. Thanks to a specific and proprietary demodulation algorithm, NanoLockin can extract from those data valuable quantities like the Specific Absorption Rate (SAR) and the Intrinsic Loss Power (ILP) with unprecedented accuracy.
The measurement is extremely fast, very sensitive, non-invasive and highly reproducible.